In vitro activity of echinocandins against non-Candida albicans: Is echinocandin antifungal activity the same?

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 29, Issue SUPPL. 2, 2011, Pages 3-9

  Espinel Ingroff, Ana ^a   Cantón, Emilia ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Echinocandin CBPs or non Candida albicans; Echinocandin ECVs for non Candida albicans; Echinocandins; Echinocandins activity non Candida albicans

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; MICAFUNGIN; PYRROLE DERIVATIVE;

AMINO ACID SUBSTITUTION; ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS FUMIGATUS; CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA METAPSILOSIS; CANDIDA ORTHOPSILOSIS; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CLAVISPORA LUSITANIAE; DRUG EFFICACY; FUNGUS ISOLATION; GENE MUTATION; IC 50; IN VITRO STUDY; KLUYVEROMYCES MARXIANUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PICHIA GUILLIERMONDII;

CANDIDA; CANDIDIASIS; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, FUNGAL; DRUG RESISTANCE, MULTIPLE, FUNGAL; ECHINOCANDINS; FLUCONAZOLE; FUNGAL PROTEINS; GLUCOSYLTRANSFERASES; HUMANS; LIPOPEPTIDES; MICROBIAL SENSITIVITY TESTS; SPECIES SPECIFICITY; THERAPEUTIC EQUIVALENCY;

EID: 79953214056     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/S0213-005X(11)70002-7     Document Type: Article

References (54)

1. M.C. Arendrup, K. Fuursted, B. Gahrn-Hansen, H.C. Schonheyder, J.D. Knudsen, and I.M. Jensen Semi-national surveillance of fungemia in Denmark 2004-2006: increasing incidence of fungemia and numbers of isolates with reduced azole susceptibility Clin Microbiol Infect 14 2008 487 494 (Pubitemid 351513938)
2. P.G. Pappas, C.A. Kauffman, D. Andes, D.K. Benjamin Jr, T.F. Calandra, and J.E. Edwards Jr Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America Clin Infect Dis 48 2009 503 535
3. Antimicrob Agents Chemother New antimicrobial agents approved by the U.S. Food and Drug Administration in 2003 and new indications for previously approved agents Antimicrob Agents Chemother 48 2004 1438 1439
4. Antimicrob Agents Chemother New antimicrobial agents approved by the U.S. Food and Drug Administration in 2004 and new indications for previously approved agents Antimicrob Agents Chemother 49 2005 2151
5. Antimicrob Agents Chemother New antimicrobial agents approved by the U.S. Food and Drug Administration in 2005 and new indications for previously approved agents Antimicrob Agents Chemother 50 2007 1912
6. M.A. Pfaller, L. Boyken, R.J. Hollis, J. Kroeger, S.A. Messer, and S. Tendolkar Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp J Clin Microbiol 48 2010 52 56
7. A. Espinel-Ingroff, E. Canton, and J. Pemán Emerging resistance to azoles and echinocandins: clinical relevance and laboratory detection Current Fungal Infection Reports 4 2010 186 195
8. A. Espinel-Ingroff In vitro antifungal activities of anidulafungin and micafungin licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal pathogens: review of the literature Rev Iberoam Micol 20 2003 121 136 (Pubitemid 38724618)
9. S.A. Messer, D.J. Diekema, L. Boyken, S. Tendolkar, R.J. Hollis, and M.A. Pfaller Activities of micafungin against 315 invasive clinical isolates of fluconazole resistant Candida spp J Clin Microbiol 44 2006 324 326 (Pubitemid 43222217)
10. L. Ostrosky-Zeichner, J.H. Rex, P.G. Pappas, R.J. Hamill, R.A. Larson, and H.W. Horowitz Antifungal susceptibilty survey of 2000 bloodstream Candida isolates in the United States Antimicrob Agents Chemother 47 2003 3149 3154 (Pubitemid 37229571)
11. J. Mora-Duarte, R. Betts, C. Rotsein, A.L. Colombo, L. Thompson-Moya, and J. Smietana Comparison of caspofungin and amphotericin B for invasive candidiasis N Engl J Med 347 2002 2020 2029 (Pubitemid 35461658)
12. E.R. Kuse, P. Chetchotisakd, C.A. Da Cunha, M. Ruhnke, C. Barrios, and D. Raghunadhrao Micafungin versus liposomal amphotericin B for candidaemia and invasive candidiasis: a phase III randomised double-blind trial Lancet 369 2007 1519 1527 (Pubitemid 46670281)
13. D.S. Krause, J. Reinhardt, J.A. Vazquez, A. Reboli, B.P. Goldstein, and M. Wible Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia Antimicrob Agents Chemother 48 2004 2021 2024 (Pubitemid 38691592)
14. L. Ostrosky-Zeichner, D. Kontoyiannis, J. Raffalli, K.M. Mullane, J. Vazquez, and E.J. Anaissie International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia Eur J Clin Microbiol Infect Dis 24 2005 654 661 (Pubitemid 41667052)
15. A.L. Colombo, A.l. Ngai, M. Bourque, S.K. Bradshaw, K.M. Strohmaier, and E.F. Taylor Caspofungin use in patients with invasive candidiasis caused common non-albicans Candida species: review of the caspofungin database Antimicrob Agents Chemother 54 2010 1864 1871
16. A.C. Reboli, C. Rotstein, P.G. Pappas, S.W. Chapman, D.H. Kett, and D. Kumar Anidulafungin versus fluconazole for invasive candidiasis N Engl J Med 356 2007 2472 2482 (Pubitemid 46919773)
17. A. Espinel-Ingroff, E. Canton, E. Martin-Mazuelos, and J. Pemán Pharmacotherapy of Candida infections with echinocandins Clin Med Therapeutics 1 2009 889 897
18. A. Dalhoff, P.G. Ambrose, and J.W. Mouton A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints Infection 37 2009 296 305
19. A. Espinel-Ingroff Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991(L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts J Clin Microbiol 36 1998 2950 2956 (Pubitemid 28429420)
20. F.C. Odds, M. Motyl, R. Andrade, J. Bille, E. Canton, and M. Cuenca-Estrella Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species J Clin Microbiol 42 2004 3475 3482 (Pubitemid 39045669)
21. Clinical and Laboratory Standards Institute Reference method for broth dilution antifungal susceptibility testing of yeasts Approved standard 3rd ed. 2008 Clinical and Laboratory Standards Institute, Wayne, PA CLSI document M27-A3
22. Clinical and Laboratory Standards Institute Reference method for broth dilution antifungal susceptibility testing of yeasts. Informational supplement 3rd ed. 2008 Clinical and Laboratory Standards Institute, Wayne, PA CLSI document M27-S3
23. Clinical and Laboratory Standards Institute Method for antifungal disk diffusion susceptibility testing of yeasts. Approved standard 2nd ed. 2009 Clinical and Laboratory Standards Institute, Wayne, PA CLSI M44-A2 document
24. Clinical and Laboratory Standards Institute Zone diameter interpretive standards, corresponding minimal inhibitory concentration (MIC) interpretive breakpoints, and quality control limits for antifungal disk diffusion susceptibility testing of yeasts. Informational supplement 3rd ed. 2009 Clinical and Laboratory Standards Institute, Wayne, PA CLSI M44-S3 document.
25. M.A. Pfaller, D.J. Diekema, D. Andes, M.C. Arendrup, S.D. Brown, and M. Motyl Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria Drug Resist Updat In press 2010
26. M.C. Arendrup, G. García-Effron, C. Lass-Florl, A. Gómez Lopes, J.L. Rodríguez-Tudela, and M. Cuenca-Estrella Echinocandins susceptibility testing of Candida species: comparison of EUCAST Edef 7.1, CLSI M27-A3, Etest, disk diffusion and agar dilution methods with RPMI and isoSensitest media Antimicrob Agents Chemother 52 2010 426 439
27. M.D. Jacobsen, J.A. Whyte, and F.C. Odds Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro Antimicrob Agents Chemother 51 2007 1882 1884 (Pubitemid 46744181)
28. C.D. Pfeiffer, G. García-Effron, A.K. Zaas, J.R. Perfect, D.S. Perlin, and B.D. Alexander Breakthrough invasive candidiasis in patients on micafungin J Clin Microbiol 48 2010 2373 2380
29. G. García-Effron, S. Park, and D.S. Perlin Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints Antimicrob Agents Chemother 53 2009 112 122
30. G. García-Effron, S. Lee, S. Park, J.D. Cleary, and D.S. Perlin Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-ß-D-glucan synthase: implication for the existing susceptibility breakpoint Antimicrob Agents Chemother 53 2009 3690 3699
31. M.-T. Baixench, N. Aoun, M. Desnos-Ollivier, D. García-Hermoso, S. Bretagne, and S. Ramires Acquired resistance to echinocandins in Candida albicans: case report and review J Antimicrob Chemother 59 2007 1076 1083 (Pubitemid 47073317)
32. M. Desnos-Ollivier, S. Bretagne, D. Raoux, D. Hoinard, F. Dromer, and E. Dannaoui Mutations in the fks1 gene in Candida albicans, C. tropicalis and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing Antimicrob Agents Chemother 52 2008 3092 3098
33. J.D. Cleary, G. García-Effron, S.W. Chapman, and D. Perlin Reduced Candida glabrata susceptibility secondary to an FSK1 mutation developed during candidemia treatment Antimicrob Agents Chemother 52 2008 2263 2265 (Pubitemid 351758575)
34. G.R. Thompson, N.P. Wiederhold, A.C. Vallor, N.C. Villareal, J.S. Lewis, and T.F. Patterson Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection Antimicrob Agents Chemother 52 2008 3783 3785
35. N.P. Wiederhold, L.K. Najvar, R. Bocanegra, D. Molina, M. Olivo, and J.R. Graybill In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera Antimicrob Agents Chemother 51 2007 1616 1620 (Pubitemid 46744135)
36. M. Castanheira, L.N. Woosley, D.J. Diekema, S.A. Messer, R.N. Jones, and M.A. Pfaller Low prevalence of fks1 hotspot 1 mutations in a worldwide collection of Candida spp Antimicrob Agents Chemother 54 2010 2655 2659
37. J.N. Kahn, G. García-Effron, M.J. Hsu, S. Park, K.A. Marr, and D.S. Perlin Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase Antimicrob Agents Chemother 51 2007 1876 1878 (Pubitemid 46744179)
38. G. García-Effron, D.J. Chua, R. Thomada, J. Dipersio, D.S. Perlin, and M. Ghannoum Novel FKs mutations associated with echinocandin resistance Antimicrob Agents Chemother 54 2010 2225 2227
39. G. García-Effron, D.P. Kontoyiannis, R.E. Lewis, and D.S. Perlin Caspofungin resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies Antimicrob Agents Chemother 52 2008 4181 4183
40. G. García-Effron, S.K. Katiyar, S. Park, Edlin T.D., and D.S. Perlin A naturally ocurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility Antimicrob Agents Chemother 52 2008 2305 2312 (Pubitemid 351915657)
41. E. Cantón, A. Espinel-Ingroff, J. Pemán, and L. Del Castillos In vitro fungicidal activities of echinocandins against Candida metapsilosi, C. orthopsilosis, C. parapsilosis by time kill studies Antimicrob Agents Chemother 54 2010 2194 2197
42. S.R. Lockart, S.A. Messer, M.A. Pfaller, and D.J. Diekema Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis J Clin Microbiol 46 2008 2659 2664
43. P. Paderu, G. García-Effron, S. Balashov, G. Delmas, S. Park, and D.S. Perlin Serum differentially alters the antifungal properties of echinocandin drugs Antimicrob Agents Chemother 51 2007 2253 2256 (Pubitemid 46903131)
44. M.A. Ghannoum, A. Chen, M. Buhari, J. Chandra, P.K. Mukherjee, and D. Baxa Differential in vitro activity of andulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit Clin Infect Dis 15 2009 274 279
45. D. Andes, D.J. Diekema, M.A. Pfaller, J. Bohrmuller, K. Marchillo, and A. Lepak In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species Antimicrob Agents Chemother 54 2010 2497 2506
46. L. Maródi, J.R. Forehand, and R.B. Johnston Jr. Mechanisms of host defence against Candida species. II. Biochemical basis for the killing of Candida by mononuclear phagocytes J Immunol 146 1991 2790 2794
47. E. Cantón, J. Pemán, A. Valentín, A. Espinel-Ingroff, and M. Gobernado In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies Antimicrob Agents Chemother 53 2009 3108 3111
48. E. Ernst, E. Roling, C. Petzold, D. Keele, and M. Klepser In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies Antimicrob Agents Chemother 46 2002 3846 3853 (Pubitemid 35403260)
49. E. Cantón, J. Pemán, M. Sastre, M. Romero, and A. Espinel-Ingroff Killing kinetics of caspofungin, micafungin,and amphotericin B against Candida guilliermondii Antimicrob Agents Chemother 50 2006 2829 2832 (Pubitemid 44198707)
50. F. Barchiesi, E. Spreghini, S. Tomassetti, A. Della Vittoria, D. Arzeni, and E. Manso Effects of caspofungin against Candida guilliermondii and Candida parapsilosis Antimicrob Agents Chemother 50 2006 2719 2727 (Pubitemid 44198693)
51. J. Cota, M. Carden, J.R. Graybill, L.K. Najvar, D.S. Burgess, and N.P. Wiederhold In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility. Antimicrob Agents Chemother 50 2006 3926 3928 (Pubitemid 44684919)
52. E. Cantón, J. Pemán, A. Valentín, M. Bosch, and A. Espinel-Ingroff Pharmacodynamics of anidulafungin against six Candida species J Chemother 19 Suppl 3 2007 42
53. M. Gobernado, and E. Cantón Aniduladungina Rev Esp Quimioterap 21 2008 99 114
54. I. Varga, G. Sóczo, G. Kardos, and L. Majoros Time-kill studies investigating the killing activity of caspofungin against Candida dubliniensis: comparing RPMI-1640 and antibiotic medium 3 J Antimicrob Chemother 62 2008 149 152 (Pubitemid 351865888)